261 related articles for article (PubMed ID: 24207030)
1. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
Khunti K; Cos X; Rutten G
Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
[TBL] [Abstract][Full Text] [Related]
2. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
[TBL] [Abstract][Full Text] [Related]
3. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
Ross S; Dzida G; Ji Q; Kaiser M; Ligthelm R; Meneghini L; Nazeri A; Orozco-Beltran D; Pan C; Svendsen AL;
J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141
[TBL] [Abstract][Full Text] [Related]
4. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
Berard L; MacNeill G
Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
[TBL] [Abstract][Full Text] [Related]
5. Insulin degludec. Uncertainty over cardiovascular harms.
Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
[TBL] [Abstract][Full Text] [Related]
6. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
Vedtofte L; Knop FK; Vilsbøll T
Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
[TBL] [Abstract][Full Text] [Related]
7. Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes.
Med Lett Drugs Ther; 2017 Sep; 59(1529):147-149. PubMed ID: 28880845
[No Abstract] [Full Text] [Related]
8. Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.
Dardano A; Bianchi C; Del Prato S; Miccoli R
Vasc Health Risk Manag; 2014; 10():465-75. PubMed ID: 25143741
[TBL] [Abstract][Full Text] [Related]
9. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.
Hirsch IB; Buse JB; Leahy J; McGill JB; Peters A; Rodbard HW; Rubin RR; Skyler JS; Verderese CA; Riddle MC
Diabetes Obes Metab; 2014 Mar; 16(3):206-14. PubMed ID: 23711193
[TBL] [Abstract][Full Text] [Related]
10. Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?
Simpson R; King A
Expert Rev Clin Pharmacol; 2015 Mar; 8(2):179-88. PubMed ID: 25697410
[TBL] [Abstract][Full Text] [Related]
11. Treating to target in type 2 diabetes: the BEGIN trial programme.
Wangnoo SK; Chowdhury S; Rao PV
J Assoc Physicians India; 2014 Jan; 62(1 Suppl):21-6. PubMed ID: 25330628
[TBL] [Abstract][Full Text] [Related]
12. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
[TBL] [Abstract][Full Text] [Related]
13. Insulin degludec for diabetes mellitus.
Drug Ther Bull; 2013 Jul; 51(7):78-81. PubMed ID: 23842634
[TBL] [Abstract][Full Text] [Related]
14. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
[TBL] [Abstract][Full Text] [Related]
15. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
[TBL] [Abstract][Full Text] [Related]
16. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
Owens DR; Matfin G; Monnier L
Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
[TBL] [Abstract][Full Text] [Related]
17. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.
Vora J; Heise T
Diabetes Obes Metab; 2013 Aug; 15(8):701-12. PubMed ID: 23451796
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of the co-formulation of insulin degludec and insulin aspart.
Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
[TBL] [Abstract][Full Text] [Related]
19. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
Muñoz Torres M
Endocrinol Nutr; 2014 Mar; 61(3):153-9. PubMed ID: 23890782
[TBL] [Abstract][Full Text] [Related]
20. Insulin degludec + liraglutide: a complementary combination.
Stinkens K; Peene B; Mathieu C
Expert Opin Biol Ther; 2016 Sep; 16(9):1171-7. PubMed ID: 27484310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
